Notably, EA treatment largely prevented these WD-TBI-induced losses of p-GSK3β and p-Akt in the cortex of the WD+EA group (WD group vs. WD+EA group, p < 0.05, Figure 6B). The gene discussed is GSK3B; the disease is Wilson disease.